文献速递生殖医学

促排卵过程中窦卵泡暴露于醋酸甲羟孕酮不会导致孕激素促排周期颗粒细胞促性腺激素反应性和类固醇生成功能的分子扰动

Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles.
PubMed 文献 · Hum Reprod · 2024-01-01

本研究纳入55例正常反应的IVF患者,比较MPA孕激素促排方案与GnRH拮抗剂方案下黄素化壁颗粒细胞的分子特征。结果显示两组在促性腺激素受体表达、对促性腺激素的反应及类固醇生成功能上均无 meaningful 差异。

要点

  • MPA孕激素促排方案与GnRH拮抗剂方案的IVF临床特征相似,包括卵巢反应、成熟卵母细胞数和受精率。
  • 两组颗粒细胞中性类固醇合成酶、胆固醇摄取/储存/利用相关基因及促性腺激素、雌激素、孕激素受体表达相似。
  • 两组基础及hCG诱导的3β-HSD表达和孕酮产生、基础及FSH诱导的芳香化酶表达和E2输出均无 meaningful 差异。

核心结论

  • 孕激素促排周期与传统GnRH拮抗剂周期在临床IVF特征及分子水平的促性腺激素受体表达、反应和类固醇生成功能上相同。
  • 本研究提供令人安心的分子证据:卵泡生长阶段窦卵泡暴露于MPA与GnRH拮抗剂周期相比,对类固醇生成、排卵和黄体功能无有害影响。

研究设计与样本

  • 临床转化研究,纳入55例正常反应的IVF患者,接受MPA孕激素促排(5 mg每日两次)或GnRH拮抗剂醋酸西曲瑞克促排。
  • 促排卵使用重组FSH,触发排卵使用重组hCG;取卵时获取黄素化壁颗粒细胞进行实验。
  • 实验方法包括细胞培养、实时定量PCR、免疫印迹、共聚焦延时活细胞成像和激素测定。

主要发现

  • 两组人口学和IVF周期特征相似,包括卵巢反应、成熟卵母细胞获率和受精率。
  • 两组颗粒细胞中性类固醇合成酶(StAR、SCC、3β-HSD、17β-HSD、芳香化酶)及胆固醇摄取/储存/利用相关基因(LDL受体、激素敏感性脂肪酶、HMG-CoA还原酶、SOAT1)表达相当。
  • 两组促性腺激素、雌激素和孕激素受体表达相似。
  • 两组基础及hCG诱导的3β-HSD表达和孕酮产生、基础及FSH诱导的芳香化酶表达和E2输出均无 meaningful 差异。
  • 两组基础及hCG诱导的LDL受体表达上调和胆固醇摄取无差异;共聚焦成像显示类固醇合成酶表达模式及其与线粒体共定位相似。

临床怎么用

  • 作者认为,本研究提供令人安心的分子证据,孕激素促排周期中卵泡生长阶段窦卵泡暴露于MPA与GnRH拮抗剂周期相比,对类固醇生成、排卵和黄体功能无有害影响。

局限性

  • 数据来自以hCG触发排卵的正常反应患者,解释时需谨慎。
  • 所评估的分子参数是否因不孕病因、卵巢反应程度、触发方式及其他潜在卵巢病理或系统性疾病而异尚不清楚。
  • MPA是本研究使用的孕激素,这些发现能否推广至其他孕激素尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does medroxyprogesterone acetate (MPA) exposure in progestin-primed ovarian stimulation (PPOS) cycles cause molecular perturbations in the steroidogenic function and gonadotropin responsiveness of the granulosa cells? SUMMARY ANSWER: PPOS cycles are identical to traditional GnRH antagonist cycles not only for clinical IVF characteristics but also for gonadotropin receptor expression, response to gonadotropins, and steroidogenic function at the molecular level. WHAT IS KNOWN ALREADY: PPOS is increasingly used as an alternative to GnRH antagonists due to the inhibitory effect of progesterone on LH release by reducing GnRH pulsatility at the hypothalamic level. Although a growing body of evidence from clinical studies did not indicate significant differences between PPOS and antagonist protocols for IVF cycle characteristics and obstetrical outcomes, it is still unknown whether exposure of the antral follicle cohort to progesterone or its synthetic derivatives during ovarian stimulation causes any subtle molecular aberrations in terms of steroidogenesis and gonadotropin responsiveness. To address this issue, detailed comparative molecular analyses were conducted in the luteinized mural granulosa cells (GCs) obtained from normal responding IVF patients undergoing PPOS and antagonist cycles. STUDY DESIGN, SIZE, DURATION: A clinical translational research study was conducted with IVF patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study included 55 normal responding IVF patients who underwent ovarian stimulation with either PPOS using MPA (5 mg twice daily) or GnRH antagonist cetrorelix acetate. Recombinant forms of FSH and hCG were used for ovarian stimulation and ovulation triggering, respectively. Luteinized mural GCs obtained during the oocyte retrieval procedure were used for the experiments. Cell culture, quantitative real-time PCR, immunoblotting, confocal time-lapse live cell imaging, and hormone assays were used. MAIN RESULTS AND THE ROLE OF CHANCE: Demographic and IVF cycle characteristics of the patients undergoing ovarian stimulation with PPOS and GnRH antagonist were similar, including ovarian response, mature oocyte yield, and fertilization rates. Molecular analyses revealed that the expression of the enzymes involved in sex-steroid synthesis (StAR, SCC, 3β-HSD, 17β-HSD, aromatase) and the uptake/storage/utilization of cholesterol (LDL receptor, Hormone-sensitive lipase, hydroxy-methyl glutaryl Co-enzyme-A reductase, and Sterol O-acyltransferase1) in the GCs of the PPOS cycles were comparable to those of the antagonist cycles. The expression of the receptors for gonadotropins, estrogen, and progesterone hormones was also similar. Basal and hCG-induced increases in 3β-HSD expression and progesterone production and basal and FSH-induced increases in aromatase expression and E2 output of the GCs from PPOS patients did not exhibit any meaningful differences when compared with GCs from antagonist cycles. Furthermore, basal and hCG-induced up-regulation in the LDL receptor expression and cholesterol uptake did not differ between the groups. Confocal imaging also revealed similar patterns of expression for the steroidogenic enzymes and their co-localization with mitochondria. Lastly, the expression of the other important genes regulating cumulus expansion, ovulation, and luteal function [Relaxin, ADAMTS-1, and epidermal growth factor (EGF)-like growth factor amphiregulin] in the GCs of the PPOS and antagonist cycles were similar. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Caution should be exercised when interpreting our data which was derived from normally responding patients whose ovulation was triggered with hCG. It is unclear whether the molecular parameters assessed vary according to infertility etiologies, magnitude of ovarian response, mode of trigger, and any other underlying ovarian pathologies or systemic diseases. MPA was the progestin used for PPOS and whether these findings can be generalized to other progestins is unknown. WIDER IMPLICATIONS OF THE FINDINGS: This study provides reassuring molecular evidence that exposure of antral follicle cohorts to MPA during the follicular growth phase does not have any detrimental effects on steroidogenic, ovulatory, and luteal functions when compared with GnRH antagonist cycles. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the School of Medicine, the Graduate School of Health Sciences of Koc University and Koç University Research Center for Translational Medicine (KUTTAM), and equally funded by the Republic of Turkey Ministry of Development Research Infrastructure Support Program. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Oktem O, Esmaeilian Y, İltumur E, et al. Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles. Hum Reprod. 2024. PMID: 39180767. doi:10.1093/humrep/deae189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。